Koyanagi Kazuo, Bilchik Anton J, Saha Sukamal, Turner Roderick R, Wiese David, McCarter Martin, Shen Perry, Deacon Linda, Elashoff David, Hoon Dave S B
Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California 90404, USA.
Clin Cancer Res. 2008 Nov 15;14(22):7391-6. doi: 10.1158/1078-0432.CCR-08-0290.
Nodal micrometastasis and circulating tumor cells detected by multimarker quantitative real-time reverse transcription-PCR (qRT-PCR) may have prognostic importance in patients with colorectal cancer.
Paraffin-embedded sentinel lymph nodes from 67 patients and blood from 34 of these patients were evaluated in a prospective multicenter trial of sentinel lymph node mapping in colorectal cancer. Sentinel lymph nodes were examined by H&E staining and cytokeratin immunohistochemistry. Sentinel lymph nodes and blood were examined by a four-marker qRT-PCR assay (c-MET, melanoma antigen gene-A3 family, beta1-->4-N-acetylgalactosaminyltransferase, and cytokeratin-20); qRT-PCR results were correlated with disease stage and outcome.
In H&E-negative sentinel lymph node patients that recurred, cytokeratin immunohistochemistry and qRT-PCR detected metastasis in 30% and 60% of patients, respectively. Disease-free survival differed significantly by multimarker qRT-PCR upstaged sentinel lymph node (P = 0.014). qRT-PCR analysis of blood for circulating tumor cells correlated with overall survival (P = 0.040).
Molecular assessment for micrometastasis in sentinel lymph node and blood specimens may help identify patients at high risk for recurrent colorectal cancer, who could benefit from adjuvant therapy.
通过多标志物定量实时逆转录聚合酶链反应(qRT-PCR)检测到的淋巴结微转移和循环肿瘤细胞可能对结直肠癌患者具有预后意义。
在一项结直肠癌前哨淋巴结定位的前瞻性多中心试验中,对67例患者的石蜡包埋前哨淋巴结以及其中34例患者的血液进行了评估。前哨淋巴结通过苏木精-伊红染色(H&E)和细胞角蛋白免疫组织化学检查。前哨淋巴结和血液通过四标志物qRT-PCR检测法(c-MET、黑色素瘤抗原基因A3家族、β1→4-N-乙酰半乳糖胺基转移酶和细胞角蛋白-20)进行检测;qRT-PCR结果与疾病分期和预后相关。
在复发的H&E阴性前哨淋巴结患者中,细胞角蛋白免疫组织化学和qRT-PCR分别在30%和60%的患者中检测到转移。多标志物qRT-PCR上调分期的前哨淋巴结患者的无病生存期有显著差异(P = 0.014)。对血液中循环肿瘤细胞进行qRT-PCR分析与总生存期相关(P = 0.040)。
对前哨淋巴结和血液标本进行微转移的分子评估可能有助于识别复发性结直肠癌高危患者,这些患者可能从辅助治疗中获益。